Article
Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.
Transfusion - 1 Jun 2017
Anani Waseem Q, Marchan Marisela G, Bensing Kathleen M, Schanen Michael, Piefer Cindy, Gottschall Jerome L, Denomme Gregory A
Abstract excerpt
BACKGROUND: Anti-CD38 therapy causes interference with both the direct and the indirect antiglobulin tests. We describe the experience from an Immunohematology Reference Laboratory and model cost options for providing safe transfusions. STUDY DESIGN AND METHODS: Phenotyping, genotyping, and antibody identification orders were retrospectively reviewed in the setting of anti-CD38 therapy. The data were used to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.